Table 2.
Univariate and multivariate analyses of the risk factors for PHT_ANC.
| Variables | PHT_ANC (n = 97) | Non-PHT_ANC (n = 114) | OR (univariable) | OR (multivariable) |
|---|---|---|---|---|
| Age (years) | 60 (42–74) | 58 (37–75) | 1.08 (0.67–1.13, p = 0.103) | |
| Gender, male | 53 (54.6) | 60 (52.6) | 2.05 (0.84–3.16, p = 0.39) | |
| R-ISS stage III | 57 (58.8) | 66 (57.9) | 2.37 (0.41–4.15, p = 0.218) | |
| Type of myeloma, IgG | 64 (65.9) | 72 (63.2) | 1.16 (0.73–1.93, p = 0.419) | |
| Type of CAR-T cell therapy | ||||
| BCMA (reference) | 21 (21.6) | 28 (24.6) | ||
| GPRC5D | 24 (24.7) | 30 (26.3) | 1.13 (0.65–1.93, p = 0.209) | |
| BCMA+CD19 | 36 (37.1) | 51 (44.7) | 1.67 (0.49–2.17, p = 0.452) | |
| BCMA+GPRC5D | 16 (16.5) | 5 (4.4) | 1.89 (0.77–2.35, p = 0.503) | |
| High tumor burdena | 31 (31.9) | 25 (21.9) | 2.21 (1.09–3.76, p = 0.013) | 1.96 (1.12–2.83, p = 0.017) |
| High-risk cytogenetic featuresb | 28 (28.9) | 26 (22.8) | 2.18 (0.67–3.98, p = 0.65) | |
| Extramedullary lesionsc | 40 (41.2) | 37 (32.5) | 1.33 (0.43–2.54, p = 0.288) | |
| Previous HCT | 27 (27.8) | 36 (31.6) | 0.86 (0.52–1.94, p = 0.522) | |
| Previous therapy lines | 4 (2–14) | 4 (2–10) | 1.28 (0.66–1.53, p = 0.591) | |
| Neutrophil count, × 109/L | 1.8 (1.3–3.2) | 2.1 (1.2–3.1) | 1.16 (0.84–1.33, p = 0.098) | |
| Hemoglobin, g/L | 91 (85–110) | 94 (83–112) | 1.29 (0.75–1.69, p = 0.106) | |
| Platelet count, × 109/L | 95 (69–136) | 106 (75–142) | 1.09 (1.03–1.87, p = 0.032) | 1.21 (0.89–1.94, p = 0.215) |
| Ferritin, ng/ml | 350.9 (225.6–887) | 318 (191.6–798) | 1.67 (1.25–4.15, p = 0.002) | 1.67 (1.15–3.28, p = 0.024) |
| CRP, mg/L | 5 (2.4–12) | 4 (0.6–9) | 1.58 (1.26–2.65, p = 0.025) | 1.44 (0.79–2.09, p = 0.35) |
| IL-6, pg/ml | 9 (5.3–23) | 7 (2.8–10) | 1.38 (1.04–2.13, p = 0.015) | 1.33 (0.87–2.03, p = 0.452) |
| IL-8, pg/ml | 5.8 (2.3–29.3) | 5.9 (1.78–22.9) | 1.29 (0.67–1.25, p = 0.511) | |
| IL-10, pg/ml | 3.2 (1.8–7.7) | 2.9 (1.6–5.9) | 2.06 (0.54–3.32, p = 0.214) | |
| INF-α, pg/ml | 4.5 (1.4–12) | 4.2 (1.6–10.2) | 1.98 (0.55–2.61, p = 0.332) | |
| INF-γ, pg/ml | 11.5 (7.7–42.5) | 5.8 (3.5–20.4) | 1.48 (1.21–1.88, p = 0.018) | 1.27 (1.12–1.99, p = 0.028) |
| LDH, U/L | 195 (180–337) | 198 (178–347) | 2.81 (0.511–3.19, p = 0.202) | |
| BMI, kg/m2 | 21.9 (18.8–28.1) | 22.4 (18.3–29.8) | 1.31 (0.84–2.93, p = 0.219) | |
| CONUT score | 5 (3–7) | 3 (2–6) | 2.12 (1.47–2.87, p = 0.011) | 2.09 (1.32–3.75, p = 0.012) |
Characteristics are summarized as median (interquartile ranges) or frequency (%).
aHigh tumor burden: defined as ≥50% clonal plasma cells or bone marrow plasma cells.
bHigh-risk cytogenetics was reported by investigators based on fluorescence in situ hybridization. A high-risk cytogenetic profile was defined by the presence of the following abnormalities: del(17p), t (4;14), or t (14; 16).
cExtramedullary diseases included tissue masses in extraosseous locations and bone-related plasmacytomas.
Bold type highlights statistically significant results (defined as p < 0.05 using the Wald test).